NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)
NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)
This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare the efficacy, safety and tolerability of NN1250 (insulin degludec ([Deg]) with insulin detemir (IDet), both combined with insulin aspart.
The main period is registered internally at Novo Nordisk as NN1250-3585 while the extension period is registered as NN1250-3725.
Inclusion Criteria:
Exclusion Criteria:
Caba, C1440AAD, Argentina
Ciudad Autónoma de Bs As, C1426ABP, Argentina
Dhantoli, Nagpur, 440012, India
New Dehli, 110029, India
Ramdaspeth / Nagpur, 440010, India
Thriruvananthapuram, 695 032, India
Gazi, 98124, Italy
Chuo-ku, Tokyo, 103 0002, Japan
Ebina-shi, 243 0432, Japan
Imizu-shi, 939 0363, Japan
Kumamoto-shi,Kumamoto, 862 0976, Japan
Naka-shi, Ibaraki, 311 0113, Japan
Nishinomiya-shi, Hygo, 662 0971, Japan
Ota-ku, Tokyo, 144 0035, Japan